For research use only. Not for therapeutic Use.
Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM[1].
Zasocitinib (10 μM) exhibits inhibitory effect on Tyk2 and JAK by targeting Tyk2 JH1 and JAK JH1 domain with inhibition rates <50%, respectively[1].
Zasocitinib inhibits phosphorylation induction of heterodimer complex Tyk2 /JAK2-mediated IL-12 (1.7 ng/mL) effect, with IC50 value of <0.1 μM in human peripheral blood mononuclear cell[1].
Catalog Number | I042868 |
CAS Number | 2272904-53-5 |
Synonyms | N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide |
Molecular Formula | C23H24N8O3 |
Purity | ≥95% |
InChI | InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1 |
InChIKey | BWINBHTTZLVXGT-NVXWUHKLSA-N |
SMILES | CNC1=CC(=NC2=C(C=NN12)C(=O)NC3CCC3OC)NC4=CC=CN(C4=O)C5=CC=CC=N5 |
Reference | [1]. Masse, Craig E, et al. Pyrazolopyrimidines as TYK2 inhibitors and their preparation: World Intellectual Property Organization, WO2019023468. 2019-01-31. |